Antivirals and resistance: influenza virus

Hayden, 2009, Influenza virus, 943

Garten, 2009, Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans, Science, 325, 197, 10.1126/science.1176225

Smith, 2009, Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic, Nature, 459, 1122, 10.1038/nature08182

Thompson, 2004, Influenza-associated hospitalizations in the United States, JAMA, 292, 1333, 10.1001/jama.292.11.1333

Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR. Morbidity and Mortality Weekly Report 2010, 59:1057–1062.

Pinto, 2006, The M2 proton channels of influenza A and B viruses, The Journal of Biological Chemistry, 281, 8997, 10.1074/jbc.R500020200

Jefferson, 2006, Amantadine and rimantadine for influenza A in adults, Cochrane Database of Systematic Reviews, CD001169

Fiore, 2011, Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR. Recommendations and Reports, 60, 1

Moscona, 2005, Neuraminidase inhibitors for influenza, The New England Journal of Medicine, 353, 1363, 10.1056/NEJMra050740

Matrosovich, 2004, Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium, Journal of Virology, 78, 12665, 10.1128/JVI.78.22.12665-12667.2004

Colman, 1983, Structure of the catalytic and antigenic sites in influenza virus neuraminidase, Nature, 303, 41, 10.1038/303041a0

Varghese, 1983, Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution, Nature, 303, 35, 10.1038/303035a0

Taylor, 2008, Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza, PLoS ONE, 3, e3410, 10.1371/journal.pone.0003410

Giraud, 2011, High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit, Antimicrobial Agents and Chemotherapy, 55, 433, 10.1128/AAC.00813-10

Wildschut, 2010, Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support, PLoS ONE, 5, e10938, 10.1371/journal.pone.0010938

Lee, 2009, Viral loads and duration of viral shedding in adult patients hospitalized with influenza, The Journal of Infectious Diseases, 200, 492, 10.1086/600383

Lee, 2011, Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?, The Journal of Infectious Diseases, 203, 1739, 10.1093/infdis/jir187

Lee, 2010, Outcomes of adults hospitalised with severe influenza, Thorax, 65, 510, 10.1136/thx.2009.130799

Jain, 2009, Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009, The New England Journal of Medicine, 361, 1935, 10.1056/NEJMoa0906695

Skarbinski, 2011, Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009, Clinical Infectious Diseases, 52, S50, 10.1093/cid/ciq021

Viasus, 2011, Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A (H1N1) virus infection, Chest, 10.1378/chest.10-2792

Rodriguez, 2011, Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A, The Journal of Antimicrobial Chemotherapy, 66, 1140, 10.1093/jac/dkq511

McGeer, 2007, Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada, Clinical Infectious Diseases, 45, 1568, 10.1086/523584

Falsey, 2007, Impact of rapid diagnosis on management of adults hospitalized with influenza, Archives of Internal Medicine, 167, 354, 10.1001/archinte.167.4.ioi60207

Murata, 2007, Pulmonary complications of interpandemic influenza A in hospitalized adults, The Journal of Infectious Diseases, 195, 1029, 10.1086/512160

Walsh, 2002, Clinical features of influenza A virus infection in older hospitalized persons, Journal of the American Geriatrics Society, 50, 1498, 10.1046/j.1532-5415.2002.50404.x

Lee, 2007, Factors associated with early hospital discharge of adult influenza patients, Antiviral Therapy, 12, 501, 10.1177/135965350701200408

Lee, 2011, Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia, Antiviral Therapy, 16, 237, 10.3851/IMP1722

Ison, 2010, End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease, The Journal of Infectious Diseases, 201, 1654, 10.1086/652498

Ison, 2010, Influenza, including the novel H1N1, in organ transplant patients, Current Opinion in Infectious Diseases, 23, 365, 10.1097/QCO.0b013e32833bc1c3

Kumar, 2010, Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study, The Lancet Infectious Diseases, 10, 521, 10.1016/S1473-3099(10)70133-X

Kumar, 2010, Guidance on novel influenza A/H1N1 in solid organ transplant recipients, American Journal of Transplantation, 10, 18, 10.1111/j.1600-6143.2009.02960.x

Zaia, 2009, Viral disease prevention after hematopoietic cell transplantation, Bone Marrow Transplantation, 44, 471, 10.1038/bmt.2009.258

Campbell, 2010, Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir, Annals of Internal Medicine, 152, 619, 10.7326/0003-4819-152-9-201005040-00022

Ison, 2008, Outcome of influenza infection managed with oseltamivir in lung transplant recipients, The Journal of Heart and Lung Transplantation, 27, 282, 10.1016/j.healun.2007.11.575

Vu, 2007, Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study, Clinical Infectious Disease, 45, 187, 10.1086/518985

Watcharananan, 2010, Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure, Transplant Infectious Disease, 12, 127, 10.1111/j.1399-3062.2010.00493.x

Ison, 2010, Influenza: a recurrent challenge to transplantation, Transplant Infectious Disease, 12, 95, 10.1111/j.1399-3062.2010.00501.x

Khanna, 2009, Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation, Transplant Infectious Disease, 11, 100, 10.1111/j.1399-3062.2008.00362.x

Donner, 2010, Safety of oseltamivir in pregnancy: a review of preclinical and clinical data, Drug Safety, 33, 631, 10.2165/11536370-000000000-00000

2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York City, 2009. MMWR. Morbidity and Mortality Weekly Report 2010, 59:321–326.

Cervantes-Gonzalez, 2010, Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment, Expert Review of Anti-infective Therapy, 8, 981, 10.1586/eri.10.83

Creanga, 2010, Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women, Obstetrics and Gynecology, 115, 717, 10.1097/AOG.0b013e3181d57947

Tanaka, 2009, Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women, CMAJ, 181, 55, 10.1503/cmaj.090866

Yates, 2010, Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant, Health Technology Assessment, 14, 109, 10.3310/hta14340-02

Beigi, 2011, Pharmacokinetics of oseltamivir among pregnant and nonpregnant women, American Journal of Obstetrics and Gynecology, 204, S84, 10.1016/j.ajog.2011.03.002

Greer, 2011, Pharmacokinetics of oseltamivir according to trimester of pregnancy, American Journal of Obstetrics and Gynecology, 204, S89, 10.1016/j.ajog.2011.03.005

Worley, 2008, The metabolism and transplacental transfer of oseltamivir in the ex vivo human model, Infectious Diseases in Obstetrics and Gynecology, 2008, 927574, 10.1155/2008/927574

Svensson, 2011, Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy, Pharmacoepidemiology and Drug Safety, 10.1002/pds.2194

Greer, 2010, Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications, Obstetrics and Gynecology, 115, 711, 10.1097/AOG.0b013e3181d44752

Oluyomi-Obi, 2010, Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A, Journal of Obstetrics and Gynaecology Canada, 32, 443, 10.1016/S1701-2163(16)34497-8

Schatz, 2011, Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System, American Journal of Obstetrics and Gynecology, 204, S64, 10.1016/j.ajog.2011.01.047

Diggory, 2001, Comparison of elderly people‘s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial, BMJ, 322, 577, 10.1136/bmj.322.7286.577

Cass, 1999, Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers, Clinical Pharmacokinetics, 36, 1, 10.2165/00003088-199936001-00001

Oxford, 2007, Antivirals for the treatment and prevention of epidemic and pandemic influenza, Influenza and Other Respiratory Viruses, 1, 27, 10.1111/j.1750-2659.2006.00006.x

Fritz, 1999, Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment, The Journal of Infectious Diseases, 180, 586, 10.1086/314938

Fraaij, 2011, Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection, The Journal of Infectious Diseases, 204, 777, 10.1093/infdis/jir397

Wijaya, 2011, Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus, Singapore Medical Journal, 52, 481

Busani, 2010, Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection, American Journal of Respiratory and Critical Care Medicine, 182, 1334, 10.1164/ajrccm.182.10.1334

Dohna-Schwake, 2010, Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications, Transplantation, 90, 223, 10.1097/TP.0b013e3181e0a0df

Dulek, 2010, Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus, Clinical Infectious Diseases, 50, 1493, 10.1086/652655

Harter, 2010, Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus, Clinical Infectious Diseases, 50, 1249, 10.1086/651604

Gaur, 2010, Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza, The New England Journal of Medicine, 362, 88, 10.1056/NEJMc0910893

Kidd, 2009, H1N1 pneumonitis treated with intravenous zanamivir, Lancet, 374, 1036, 10.1016/S0140-6736(09)61528-2

Renaud, 2011, H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients, Emerging Infectious Diseases, 17, 653, 10.3201/eid1704.101429

Ishizuka, 2010, Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers, Journal of Clinical Pharmacology, 50, 1319, 10.1177/0091270009356297

Yamashita, 2010, Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza, Antiviral Chemistry & Chemotherapy, 21, 71, 10.3851/IMP1688

Sugaya, 2010, Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection, Antimicrobial Agents and Chemotherapy, 54, 2575, 10.1128/AAC.01755-09

Watanabe, 2010, Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial, Clinical Infectious Diseases, 51, 1167, 10.1086/656802

Bantia, 2001, Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir, Antimicrobial Agents and Chemotherapy, 45, 1162, 10.1128/AAC.45.4.1162-1167.2001

Babu, 2000, BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design, Journal of Medicinal Chemistry, 43, 3482, 10.1021/jm0002679

Barroso, 2005, Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment, Antiviral Therapy, 10, 901, 10.1177/135965350501000805

Hernandez, 2011, Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States, Clinical Infectious Diseases, 52, 695, 10.1093/cid/cir001

Kohno, 2010, Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection, Antimicrobial Agents and Chemotherapy, 54, 4568, 10.1128/AAC.00474-10

Kohno, 2011, Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: a phase III randomized, double-blind study, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.00360-11

Kohno, 2011, Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients, Antimicrobial Agents and Chemotherapy, 55, 2803, 10.1128/AAC.01718-10

Ison, 2009, Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza

Ison, 2011, Update on phase 3 trials – IV peramivir

Birnkrant, 2009, The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza, The New England Journal of Medicine, 361, 2204, 10.1056/NEJMp0910479

Biocryst reports preliminary results from a phase II clinical trial of peramivir in subjects with acute influenza. In BioCryst Pharmaceuticals, Inc Press Release. September 19, 2009.

BioCryst provides peramivir update and reports first quarter 2009 financial results. In BioCryst Pharmaceuticals, Inc Press Release. May 8, 2009.

Malakhov, 2006, Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection, Antimicrobial Agents and Chemotherapy, 50, 1470, 10.1128/AAC.50.4.1470-1479.2006

Moscona, 2010, A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo, The Journal of Infectious Diseases, 202, 234, 10.1086/653621

Triana-Baltzer, 2010, DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis, The Journal of Antimicrobial Chemotherapy, 65, 275, 10.1093/jac/dkp421

Moss, 2011, A phase 2A dose-ranging clinical trial of DAS181 for treatment of influenza in healthy adults, V-405a

Furuta, 2009, T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections, Antiviral Research, 82, 95, 10.1016/j.antiviral.2009.02.198

Furuta, 2005, Mechanism of action of T-705 against influenza virus, Antimicrobial Agents and Chemotherapy, 49, 981, 10.1128/AAC.49.3.981-986.2005

Hayden, 2009, Developing new antiviral agents for influenza treatment: what does the future hold?, Clinical Infectious Diseases, 48, S3, 10.1086/591851

Luke, 2010, Hark back: passive immunotherapy for influenza and other serious infections, Critical Care Medicine, 38, e66, 10.1097/CCM.0b013e3181d44c1e

Ison, 2003, Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza, Antiviral Therapy, 8, 183, 10.1177/135965350300800301

Nguyen, 2010, Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro, PLoS ONE, 5, e9332, 10.1371/journal.pone.0009332

Duval, 2010, Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial, PLoS Medicine, 7, e1000362, 10.1371/journal.pmed.1000362

Astrahan, 2004, A novel method of resistance for influenza against a channel-blocking antiviral drug, Proteins, 55, 251, 10.1002/prot.20018

Hay, 1986, Molecular basis of resistance of influenza A viruses to amantadine, The Journal of Antimicrobial Chemotherapy, 18, 19, 10.1093/jac/18.Supplement_B.19

Hurt, 2006, Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors, Expert Review of Anti-infective Therapy, 4, 795, 10.1586/14787210.4.5.795

Ison, 2009, Anti-influenza therapy: the emerging challenge of resistance, Therapy, 6, 883, 10.2217/thy.09.61

Bright, 2006, Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States, JAMA, 295, 891, 10.1001/jama.295.8.joc60020

Deyde, 2007, Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide, The Journal of Infectious Diseases, 196, 249, 10.1086/518936

Bautista, 2010, Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection, The New England Journal of Medicine, 362, 1708, 10.1056/NEJMra1000449

Abdel-Ghafar, 2008, Update on avian influenza A (H5N1) virus infection in humans, The New England Journal of Medicine, 358, 261, 10.1056/NEJMra0707279

Bright, 2005, Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern, Lancet, 366, 1175, 10.1016/S0140-6736(05)67338-2

Hurt, 2009, Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses, Drugs, 69, 2523, 10.2165/11531450-000000000-00000

Lackenby, 2008, Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe, Euro Surveillance, 13

Sheu, 2010, Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing, Antiviral Research, 85, 354, 10.1016/j.antiviral.2009.10.022

Gubareva, 2010, Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro, Antiviral Therapy, 15, 1151, 10.3851/IMP1678

Brookes, 2011, Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness, The Journal of Antimicrobial Chemotherapy, 66, 466, 10.1093/jac/dkq486

Aoki, 2007, Influenza virus susceptibility and resistance to oseltamivir, Antiviral Therapy, 12, 603, 10.1177/135965350701200S04.1

Gubareva, 2004, Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors, Virus Research, 103, 199, 10.1016/j.virusres.2004.02.034

Matrosovich, 2003, Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors, Journal of Virology, 77, 8418, 10.1128/JVI.77.15.8418-8425.2003

Potier, 1979, Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate, Analytical Biochemistry, 94, 287, 10.1016/0003-2697(79)90362-2

Deyde, 2010, Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing, Antimicrobial Agents and Chemotherapy, 54, 1102, 10.1128/AAC.01417-09

Triana-Baltzer, 2011, Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181, The Journal of Antimicrobial Chemotherapy, 66, 15, 10.1093/jac/dkq387

Boltz, 2010, Drugs in development for influenza, Drugs, 70, 1349, 10.2165/11537960-000000000-00000